SCHEMBL1787541

SCHEMBL1787541

O=C(O)c1ccccc1C(=O)Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.69
TP53 P04637 1/20 0.69
ALDH1A1 P00352 5/20 0.61
ALOX15 P16050 1/20 0.61
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
AKR1B1 P15121 1/20 0.54
SRD5A2 P31213 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 1/20 0.50
LMNA P02545 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
APEX1 P27695 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129795 0.93 MEN1 (0.62) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL7663868 0.87 USP2 (0.64) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL7811204 0.87 TP53 (0.64) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL29351857 0.87 USP2 (0.64) USP2TP53ALDH1A1ALOX15KMT2A
Phthalic Acid SCHEMBL10781202 0.84 AKR1B1 (0.77) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL1358285 0.84 ALDH1A1 (0.59) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL1689462 0.84 FOLH1 (0.54) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL3244289 0.83 USP2 (0.51) USP2TP53ALDH1A1ALOX15KMT2A
SCHEMBL28705224 0.83 USP2 (0.56) USP2TP53ALDH1A1KMT2AMEN1
SCHEMBL10954405 0.83 G6PD (0.52) USP2TP53ALDH1A1ALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113004235-B Stereoselective synthesis method of (Z) -3-alkenylphthalide derivative 中国医学科学院药物研究所 2023-05-05 CN disclosed
CN-115197565-A Semi-crystalline polyamide composition based on short diamines with high glass transition temperature, method for the production thereof and use thereof 阿科玛法国公司 2022-10-18 CN disclosed
CN-110446740-B Semi-crystalline polyamide compositions based on short diamines with high glass transition temperature, method for the production thereof and use thereof 阿科玛法国公司 2022-07-12 CN disclosed
CN-110431169-B Semi-crystalline polyamide composition having a high glass transition temperature and a high melting temperature, method for preparing same and use thereof 阿科玛法国公司 2022-05-17 CN disclosed
CN-113004235-A Stereoselective synthesis method of (Z) -3-alkenyl phthalide derivative 中国医学科学院药物研究所 2021-06-22 CN disclosed
CN-107949596-B Semi-crystalline polyamide component with high glass transition temperature for composite materials, method for the production thereof and use thereof 阿科玛法国公司 2021-02-02 CN disclosed
CN-108026267-B Semi-crystalline polyamide composition with high glass transition temperature for thermoplastic materials, method for the production thereof and use thereof 阿科玛法国公司 2021-02-02 CN disclosed
US-20170112843-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE SCRIPPS RESEARCH INSTITUTE 2017-04-27 US disclosed
US-9464065-B2 Compounds and methods for inducing chondrogenesis THE SCRIPPS RESEARCH INSTITUTE (US) 2016-10-11 US disclosed
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 US disclosed
US-5624922-A Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1997-04-29 US disclosed
EP-0597540-B1 Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC (US) 1996-06-05 EP disclosed
US-5380721-A Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1995-01-10 US disclosed
EP-0597540-A1 Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1994-05-18 EP disclosed
US-5268372-A Where nitrogen in position 2 and 5 are connected by a methylene bridge STERLING WINTHROP INC. (US) 1993-12-07 US disclosed
US-5206231-A 2,5-benzodiazocine antiarrhythmic agents STERLING DRUG INC. (US) 1993-04-27 US disclosed
EP-0475527-A2 Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents STERLING DRUG INC. (US) 1992-03-18 EP disclosed
US-4841047-A ANTIALLERGENS AASTA PHARMA AG (DE) 1989-06-20 US disclosed
US-4058529-A Polycyclic amino derivatives of pyrrolidone and piperidone CIBA-GEIGY CORPORATION (US) 1977-11-15 US disclosed
US-3994920-A APPETITE SUPPRESSANT, ANTIDEPRESSANT AMERICAN HOME PRODUCTS CORPORATION (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112843-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS COL2A1, BMP4, BMP2 USP2 1657/4885TP53 816/4885ALDH1A1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.